Home › News › Biotechnology

Lupin gets US FDA nod to market generic Kerydin topical solution

Lupin gets US FDA nod to market generic Kerydin topical solution

Global pharma major Lupin Limited announced the US launch of tavaborole topical solution, 5% having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Pithampur, India.

Tavaborole topical solution, 5%, is generic equivalent of Kerydin topical solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes.

Tavaborole topical solution, 5% has an estimated annual sales of US$ 53 million in the US, according to IQVIA MAT May 2021.

Lupin gets US FDA nod to market generic Kerydin topical solution

Darshana

  • Info 1
  • Info 2
  • Info 3
More news about: biotechnology | Published by Darshana | July - 13 - 2021

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology